Skip to Content

NeoProfen Approval History

FDA Approved: Yes (First approved April 13, 2006)
Brand name: NeoProfen
Generic name: ibuprofen lysine
Dosage form: Injection
Company: Farmacon-IL, LLC
Treatment for: Patent Ductus Arteriosus

NeoProfen is an intravenous formulation of ibuprofen lysine indicated to close a clinically significant patent ductus arteriosus (PDA) in premature infants, who are no more than 32 weeks gestational age when usual medical management is ineffective.

Development History and FDA Approval Process for NeoProfen

DateArticle
Apr 13, 2006Approval NeoProfen Approved - Farmacon-IL, LLC - Treatment for Patent Ductus Arteriosus

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide